Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | MMP3 | P08254 | 5/20 | 0.49 |
| ▸ | MMP2 | P08253 | 1/20 | 0.49 |
| ▸ | CAPN1 | P07384 | 3/20 | 0.48 |
| ▸ | IL1RN | P18510 | 1/20 | 0.47 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.47 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.47 |
| ▸ | MMP9 | P14780 | 1/20 | 0.47 |
| ▸ | PSMB5 | P28074 | 3/20 | 0.47 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17948531 | 0.90 | ERAP2 (0.50) | MMP3MMP2CAPN1IL1RNERAP2 | |
| SCHEMBL10105785 | 0.88 | ALDH1A1 (0.57) | ALDH1A1THRBCYP2C9CYP2C19HSD17B10 | |
| SCHEMBL19762061 | 0.87 | ALDH1A1 (0.66) | ALDH1A1THRBCYP2C9CYP2C19HSD17B10 | |
| SCHEMBL2606643 | 0.87 | ALDH1A1 (0.66) | ALDH1A1THRBCYP2C9CYP2C19HSD17B10 | |
| SCHEMBL2605618 | 0.86 | REN (0.56) | — | |
| SCHEMBL92790 | 0.85 | PSMB5 (0.52) | PSMB5 | |
| SCHEMBL92794 | 0.85 | PSMB5 (0.52) | IL1RNERAP2ERAP1PSMB5 | |
| SCHEMBL2633286 | 0.84 | ALDH1A1 (0.50) | ALDH1A1THRBCYP2C9CYP2C19HSD17B10 | |
| SCHEMBL10105765 | 0.84 | ALDH1A1 (0.50) | ALDH1A1THRBCYP2C9CYP2C19HSD17B10 | |
| SCHEMBL10087282 | 0.84 | MME (0.60) | MMP3MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207297-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| US-20120094930-A1 | COMPOUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-8129346-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-20080200398-A1 | Compounds For Enzyme Inhibition | PROTEOLIX, INC. (US) | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200398-A1 | Compounds For Enzyme Inhibition | ANPEP, DNPEP, CPN1 | ALDH1A1 2975/4885THRB 2511/4885CYP2C9 1013/4885 |
| US-20120094930-A1 | COMPOUNDS FOR ENZYME INHIBITION | ANPEP, DNPEP, CPN1 | ALDH1A1 2975/4885THRB 2511/4885CYP2C9 1013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.